Jubilant Pharmova Ltd
NSE: JUBLPHARMA BSE: 530019
₹985
(2.85)%
Tue, 03 Feb 2026, 08:36 am
Market Cap156.22B
PE Ratio32.75
Dividend0.51
Health Technology
Pharmaceuticals: Major
24.5Kjubilant pharmova ltd History
1978
- Incorporated on 21 June in Uttar Pradesh to manufacture Vinyl Acetate Monomer; promoted by A.B. Bofors, Hindustan Wires Ltd., Mr. M.L. Bhartia.
- Entered technical collaboration with Noble Chematur Division of A.B. Bofors Sweden for VAM know-how and engineering.
1981
- 1,200 equity shares subscribed by MoA signatories; issued equity and preference shares via prospectus, reserved for UPSIDC, PICUP, promoters, AB Brothers Sweden, public subscription.
1982
- Issued 693,000 rights equity shares at par (1:5); 552,043 taken up, remainder private placement.
1983
- Signed technical collaboration with Crown Decorative Products Ltd. U.K. and Reed International for polyvinyl acetate emulsions.
- Promoted India Glycols Ltd. for MEG with Scientific Design Co. U.S.A.
1984
- Signed technical collaboration with Technimont Spa Italy for 2,000 tonnes/annum polyvinyl alcohol (commissioned 1991 at 650 MT, doubled to 1,400 MT).
1985
- Incorporated wholly owned subsidiaries Vam Leasing Ltd. and Vam Investments Ltd.
- Commissioned polyvinyl acetate emulsions plant.
1986
- Issued 1,006,180 equity shares to financial institutions on loan conversion.
1987
- Promoted Insilco Ltd. with Degussa AG for spray dried silica.
- Submitted applications to increase VAM capacity to 20,000 tonnes/annum.
- Privately placed 15% NCDs Rs 1 crore and 14% NCDs Rs 1.50 crores.
1989
- Launched Vamicol adhesive, liquid/dry CO2; installed 25 tonnes/hour boiler.
- Commissioned carbon dioxide recovery and dry ice plant.
1990
- Commissioned 500 tonnes/annum pyridine and picoline plant.
- Commissioned expanded VAM, acetic anhydride, acetic acid capacities in October.
- India Glycols Ltd. commenced MEG commercial production on 1 January.
- Privately placed 14% redeemable NCDs aggregating Rs 10 crores.
1992
- Amalgamated Ramganga Fertilizers Ltd. effective 1 April; issued 256,522 equity shares to its shareholders.
1995
- Signed technical collaborations with Kemira Coatings U.K. for wood finishes and Teutoburg Germany for construction chemicals.
- Proposed 5.5 MW turbine generator and 4,000 tonnes/annum increase in Pyridine & Picolines capacity.
1996
- Proposed Singapore offices for SE Asia, China, Europe markets.
- Capital expenditure of Rs 26.40 crores on Pyridine & Picolines, wood finishes, construction chemicals, sulphuric acid modernisation, biogas boiler.
1997
- Reported 8.97% net profit increase to Rs 23.07 crores.
- Faced sales decline due to Asian crisis and capacity build-up.
1998
- Introduced Vam Bond 2001 adhesive.
- Proposed merger of Anichem India Ltd. and Enpro Speciality Chemicals Ltd.
- Revamped fertiliser plant; increased sulphuric acid capacity to 175 tpd; commissioned 12.45 MW captive power plant.
- ICRA downgraded non-convertible debentures.
2000
- Set up Jubilant Biosys Ltd. for bio/chemo informatics.
2001
- Adopted new corporate identity: Jubilant Organosys Ltd.
2002
- Acquired Active Pharmaceutical Ingredients business.
2003
- Changed trading symbol to 'JUBILANT'.
- Jubilant Securities and Capital acquired 2.99% equity shares.
- Appointed H.K. Khan as additional director.
2004
- Approved voluntary delisting from Delhi, Calcutta, Uttar Pradesh Stock Exchanges.
- Acquired generic pharma companies in Europe.
- Signed international CRAMS contracts worth US$60 million for 2007.
2005
- Acquired US pharma company with FDA-approved facility for off-patent drugs.
- Acquired US CRO for clinical research services.
- Acquired Target Research Associates Inc. (renamed Clinsys Inc.).
- Acquired Trinity Laboratories Inc. and Trigen Laboratories Inc. (renamed Jubilant Pharmaceuticals Inc.).
- Set up wholly owned subsidiary Jubilant Clinsys Ltd.
2006
- Selected for ICSI National Award for Corporate Governance; Finalist Golden Peacock Award.
- Split face value of shares from Rs 5 to Re 1.
2007
- Acquired 100% equity in Hollister-Stier Laboratories LLC, USA.
2008
- Acquired DRAXIS Specialty Pharmaceuticals Inc., Canada.
- Acquired Speciality Molecules Pvt. Ltd.
- Formed drug development JV with Lilly.
- Secured $92 million CRAMS contracts.
2009
- Entered drug discovery partnerships with AstraZeneca, Orion, Endo, BioLeap; extended Lilly collaboration.
- Entered drug development collaborations with University of Alabama, Southern Research Institute, Duke University.
- Inaugurated Jubilant Kalpataru 120-bed hospital in Kolkata.
2010
- Company name changed to Jubilant Life Sciences Ltd.
- Signed USD 51 million CRAMS contract with Life Sciences company.
- Received ET-IMEA Platinum Award, Best CFO award.
- Appointed Shardul S. Shroff as Additional Director.
2011
- Delivered early stage milestone in Pain therapeutic area.
- Set up global scale capacities for Symtet.
2012
- Achieved early stage milestone in collaborative program.
- Jubilant HollisterStier received multi-million dollar award for sterile parenteral products.
- Inaugurated Jubilant SEZ at Bharuch by Gujarat CM.
2013
- Received NDTV Profit CSR Award.
- Received ANDA approval for Quetiapine Fumarate Tablets.
- Won Supply Chain Excellence Award.
2014
- Results of tender offer for minority shares in Cadista Holdings Inc.
- Board recommended Rs 3 per share dividend.
- Won India Pharma Awards Excellence, Golden Peacock Business Excellence.
2015
- Received multiple awards: Gold ACCQC, CIO100, Golden Peacock Quality, Dataquest IT, ASSOCHAM Responsible Organization, Sustainability Leaders, Greentech Environment, IDC Insights.
2016
- Won FICCI Sustainability Award for Best Green Process in Chemical sector.
2017
- Received USFDA approval for generic anti-fungal capsules.
- Completed acquisition of Triad's Radiopharmacy business.
- Eyes speciality pharma business acquisition in US.
- Received multiple awards including CHEMEXCIL export performance, IR Society, Green Tech Environment, CII Energy Excellence.
2018
- Setting up greenfield pesticide manufacturing unit at Bharuch.
- Received green nod for Rs 250-cr pesticide project.
- Agreement to acquire 10% stake in Inipharm Inc., USA.
- Received ANDA approval for Niacin Extended-Release Tablets USP.
2019
- Celebrated decade of Social Entrepreneur of the Year India Awards partnership.
2020
- Supported COVID-19 efforts with health/safety materials in Karnataka and free hand sanitizers.
- Launched JUBI-R (remdesivir) in India for COVID-19 treatment.
- Hindustan Times Fellowship Seed Transformation Program with Schwab Foundation.
2021
- Company name changed to Jubilant Pharmova Ltd.
- Undertaking of Jubilant Generics Limited.
2022
- Jubilant HollisterStier announced CAD 100 Mn expansion of CMO facility in Montreal, Canada.
- Jubilant HollisterStier entered $149.6 Mn cooperative agreement with US Government for vaccine manufacturing capacity expansion.
- Presented data on Isoform Selective PAD4 inhibitors at AACR Meeting.
- Received FDA clearance of IND for JBI-802, a dual LSD1 and HDAC6 inhibitor for solid tumors.
2023
- Received additional funding from Government of Canada for Montreal facility expansion.
- Radiopharma business received USFDA approval for Technetium Tc-99m Mertiatide injection.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800